跳至主要内容
临床试验/NCT04800991
NCT04800991已完成不适用

A Pilot Study to Evaluate the Feasibility and Efficacy of Digital Health Technology for Postoperative Care With Gastrectomy-Treated Patients in Gastric Cancer

Seoul National University Hospital2 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2021年3月17日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
40
试验地点
2
主要终点
Score of each domain of the 'feasibility assessment of the investigational device (application)' questionnaire for subjects

研究概览

简要总结

The objective of this pilot study is to evaluate the feasibility and efficacy of Rhexium Onco Nutrition, HDT-202 for post-operative care in patients who have undergone gastrectomy.

详细描述

  1. A total of 4 visits will be performed.
  2. At the screening visit,subject's written informed consent, assessing the inclusion/exclusion criteria and assigning enrollment numbers to eligible subjects, demographic information taking, medical history/medication history taking, vital signs measuring, physical examination, height and body weight measuring, instructing how to install/use the investigational device, and administering quality of life questionnaires.
  3. During the treatment period, a total of 3 visits will be performed. To evaluate feasibility and efficacy, the following procedures will be carried out: vital signs measuring, physical examination, nutrition assessment/consultation, evaluation of feasibility for 'subjects', evaluation of feasibility for 'investigators', and adverse events (AEs)/concomitant medications checking and collecting.
  4. During the treatment period, telephone monitoring is conducted depending on the compliance of subjects.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Supportive Care
盲法
None

入排标准

年龄范围
19 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient who voluntarily signs the informed consent form for this study
  • Age of ≥19 years old
  • Patient who has undergone therapeutic gastrectomy after a diagnosis of gastric cancer
  • Able to eat food orally after gastrectomy
  • Patient who possesses an Android OS based mobile device and is capable of using the investigational device.

排除标准

  • Other cancer or metastasis documented within 5 years prior to screening
  • Ongoing or planned enteral tube feeding or total parenteral nutrition
  • Other clinically significant medical or psychiatric findings based on which the individual is considered by the investigator to be ineligible
  • Individual who possesses a mobile device on which the application is unable to be installed and/or run normally for technical reasons
  • Individual who, in the opinion of the investigator, has difficulty understanding how to use the investigational device or is unlikely to comply with other study procedures

结局指标

主要结局

Score of each domain of the 'feasibility assessment of the investigational device (application)' questionnaire for subjects

时间窗: Week 10 (Visit 4)

higher scores mean a better outcome

Score of each domain of the 'feasibility assessment of the investigational device (website)' questionnaire for investigators

时间窗: Week 6 (Visit 3)

higher scores mean a better outcome

次要结局

  • Change from baseline (Visit 1) in 'EORTC QLQ-C30' score(baseline (Visit 1), Week 10 (Visit 4))
  • Change from baseline (Visit 1) in 'EORTC QLQ-STO22' score(baseline (Visit 1), Week 10 (Visit 4))
  • The investigational device(application) usage compliance by age(Week 10 (Visit 4))
  • The investigational device(application) usage compliance by body mass index [BMI] before discharge from hospital(Week 10 (Visit 4))
  • Change from baseline (Visit 1) in 'KOQUSS Index' score(baseline (Visit 1), Week 10 (Visit 4))
  • Frequency of each symptom between visits after using the investigational device (application)(Week 2 (Visit 2), Week 6 (Visit 3), Week 10 (Visit 4))
  • The investigational device(application) usage compliance by stage of disease(Week 10 (Visit 4))
  • The investigational device(application) usage compliance by status of postoperative anticancer therapy(Week 10 (Visit 4))
  • The investigational device(application) usage compliance by underlying disease(Week 10 (Visit 4))
  • The investigational device(application) usage compliance by gender(Week 10 (Visit 4))
  • The investigational device(application) usage compliance by surgery(Week 10 (Visit 4))
  • Correlation between change from Day 1 in body weight at Week 10 (Visit 4) and calory goal achievement rate(Week 10 (Visit 4))
  • Correlation between change from Day 1 in body weight at Week 10 (Visit 4) and protein intake goal achievement rate(Week 10 (Visit 4))

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Han-Kwang Yang

Professor

Seoul National University Hospital

研究点 (2)

Loading locations...

相似试验

NuGa (Nutrition for Gastric Cancer Patients) | 临床试验